No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer

E-ISSN： 1464-5491|35|3|381-385

ISSN： 0742-3071

Source： DIABETIC MEDICINE, Vol.35, Iss.3, 2018-03, pp. : 381-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients

By Zeliadt Steven B.

The Patient: Patient-Centered Outcomes Research, Vol. 1, Iss. 3, 2008-01 ,pp. : 189-200

Adis International

Access to resources Recommend Favorite

Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer

CLINICAL ENDOCRINOLOGY, Vol. 83, Iss. 6, 2015-12 ,pp. : 938-942

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vandetanib for aggressive and symptomatic medullary thyroid cancer

By Deshpande Hari A Carling Tobias Khan Nabeela Holt Elizabeth

Clinical Practice, Vol. 10, Iss. 3, 2013-05 ,pp. : 275-282

Future Medicine

Access to resources Recommend Favorite

Medical management of metastatic medullary thyroid cancer

CANCER, Vol. 120, Iss. 21, 2014-11 ,pp. : 3287-3301

John Wiley & Sons Inc

Access to resources Recommend Favorite

Body image perceptions among women with pre‐existing physical disability who developed breast cancer: a qualitative exploration

PSYCHO-ONCOLOGY (ELECTRONIC), Vol. 24, Iss. 12, 2015-12 ,pp. : 1826-1829

John Wiley & Sons Inc

Access to resources Recommend Favorite